Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
LaunchAmarin Corporation plc announces national reimbursement approval for VAZKEPA® in Italy to reduce cardiovascular risk in high-risk patients.
Dec 16, 2024
BridgewaterBiotechnologyHealth CarePharmaceutical
Product Description
Amarin Corporation plc has received approval from Italy’s National Health Service for national reimbursement of VAZKEPA® (icosapent ethyl), aimed at reducing cardiovascular risk in eligible high-risk patients. This marks a significant step forward in increasing patient access to the treatment across Europe.
Company Information
Company
Amarin Corporation plc
Location
Bridgewater, New Jersey, United States
About
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk for patients worldwide.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Amarin Corporation plc ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.